Marinow J, Olcay A, Schaumann W, Weiss W
Eur J Clin Pharmacol. 1977 Mar 11;11(3):213-8. doi: 10.1007/BF00606413.
The aim of the present investigation was to estimate the ratio of the intravenous doses of beta-methyl-digoxin and digoxin required to produce identical serum glycoside concentrations in man. 20 patients on intravenous maintenance therapy were changed from beta-methyl-digoxin to the identical dose of digoxin or vice versa. Each drug was given for 7 days. Serum concentrations 13% higher were found during administraton of beta-methyl-digoxin. Assuming a half life of 60 h after withdrawal, the dose of digoxin producing the same minimum serum concentration was estimated to be 1.16 times higher than that of beta-methyl-digoxin. 18 healthy volunteers received 0.4 mg beta-methyl- digoxin, and 23 the same dose of digoxin, as an intravenous infusion over 2 h. The serum concentrations and urinary glycoside excretion were measured over a period of 32 hrs. During the first hour after the infusion the serum concentration of digoxin declined more rapidly than that of beeta-methyl-digoxin. Thereafter, the ratio of the serum concentrtions did not change appreciably up to the end of the investigation. The area under the serum concentration/time curve was about 13% greater for beta-methyl-digoxin than for digoxin; this difference was not significant. The average renal clearance was 96 +- 9 ml for beta-methyl-digoxin, 151 +- 13 ml for digoxin. Since the total body clearance of digoxin is only about 1.16 times higher than that of beta-methyl-digoxin, the lower renal clearance of beta-methyl-digoxin must partly be compensated by higher extrarenal clearance. From the ratios of the areas under the serum concentration/time curves after single doses of beta-methyl-digoxin and digoxin, and the minimum serum concentrations during maintenance therapy, it was concluded that the dose of digoxin to produce the same average serum concentrations would be about 1.15 times higher than that of beta-methyl-dogoxin. In comparison wtih the large variations in individual dosage of digoxin and beta-methyl-digoxin, this difference is too small to be of practical importance.
本研究的目的是估计在人体中产生相同血清糖苷浓度所需的β-甲基地高辛和地高辛静脉剂量的比值。20名接受静脉维持治疗的患者从β-甲基地高辛换成相同剂量的地高辛,或反之。每种药物给药7天。在给予β-甲基地高辛期间发现血清浓度高13%。假设停药后半衰期为60小时,产生相同最低血清浓度的地高辛剂量估计比β-甲基地高辛高1.16倍。18名健康志愿者静脉输注0.4mgβ-甲基地高辛,23名输注相同剂量的地高辛,输注时间为2小时。在32小时内测量血清浓度和尿糖苷排泄。输注后第一小时内,地高辛的血清浓度下降比β-甲基地高辛更快。此后,直至研究结束,血清浓度比值没有明显变化。β-甲基地高辛的血清浓度/时间曲线下面积比地高辛约大13%;这种差异不显著。β-甲基地高辛的平均肾清除率为96±9ml,地高辛为151±13ml。由于地高辛的总体清除率仅比β-甲基地高辛高约1.16倍,β-甲基地高辛较低的肾清除率必须部分由较高的肾外清除率来补偿。根据单次给予β-甲基地高辛和地高辛后血清浓度/时间曲线下面积的比值以及维持治疗期间的最低血清浓度,得出产生相同平均血清浓度的地高辛剂量比β-甲基地高辛高约1.15倍。与地高辛和β-甲基地高辛个体剂量的巨大差异相比,这种差异太小,不具有实际重要性。